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Abstract
Helicobacter pylori (H. pylori) infection is tightly associated with gastrointestinal disorders such as chronic gastritis, peptic ulcer,
gastric MALToma, and gastric cancer. Decreased antibiotic susceptibility inH. pylori is a worldwide problem. Our objective was
to determine in vitro antimicrobial susceptibility of H. pylori isolates obtained from gastric mucosa biopsies of children with H.
pylori-associated gastroduodenal diseases using disk-diffusion method. A total 76 biopsy specimens were studied; antibiotic
susceptibility was assessed in case of 30 children in whomH. pyloriwas revealed by bacteriology. Themaximum resistance ofH.
pylori isolates was revealed to clarithromycin with nine resistant isolates (30.0%). The rate of resistance to metronidazole,
amoxicillin, furazolidone, tetracycline, and levofloxacin was 23.3, 33.3, 16.7, 25.0, and 16.7%, respectively.Multidrug resistance
was detected in 20.0% of H. pylori strains. The high prevalence of resistance to antibiotics used in eradication therapy is
becoming a problem which needs eradication therapy regimen use based on regional H. pylori resistance rates.
Keywords Helicobacter pylori . Children . Antibiotic susceptibility . Disk-diffusionmethod
1 Introduction
Helicobacter pylori (H. pylori) infection is tightly associated
with gastrointestinal disorders such as chronic gastritis, peptic
ulcer, gastric MALToma, and gastric cancer [1].
Almost half of the world’s population are infected by H.
pylori, and its prevalence is highly variable. High incidence of
H. pylori infection has been observed in Africa: 75–77% in
Ethiopia [2, 3] and 93.6% in Nigeria [4]; in Asia: 89% in Iran
[5], 62.3% inKazakhstan [6], and about 60% inKorea [7]; and in
the Middle East: 82.5% in Turkey [8]. H. pylori infection prev-
alence is less among the population of Saudi Arabia—36.8% [9],
and in Canada—about 30% [10].
The number of infected children also varies in different
regions. High level of H. pylori infection in children is
observed in Africa and Asia: 39.6% of children aged 1–
10 years in Madagascar [11] and 40.7% in Nigeria [12];
64% of children aged 10 to 19 years in Kazakhstan [13],
82% in Iran [5], and 50–80% in the Middle East (Saudi
Arabia, Egypt, Turkey) [14–17]; and 35% of children aged
7–14 years in Latin America are infected [18]. The prevalence
ofH. pylori among children in economically developed coun-
tries is significantly lower—about 12.2% in the USA [19] and
7% in the UK [18].
A complete data on H. pylori prevalence among adults and
children in Russian Federation is not available, only a few
regional studies were conducted. H. pylori was found to be
prevalent in 88% of adult population in Moscow [20] and in
64% in Smolensk [21]. Several regional studies evaluating
prevalence of H. pylori in children and teenagers were con-
ducted in Siberia, Perm, Ufa, Krasnoyarsk, and Kazan, indi-
cating a high level ofH. pylori infection up to 71% in Yakutia
[22], 55.2% in Tuva [23], 48% in Perm [24], 82.3% in Ufa
[25], 90% in Krasnoyarsk [26], and 59.3% in Kazan [27].
According to Maastricht V (2015), ESPGHAN and
NASPGHAN (2010) recommended that H. pylori eradication
therapy should be prescribed considering the level ofH. pylori
antibiotic resistance; particularly, the level of H. pylori
clarithromycin resistance should not exceed 15% to be able
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